Analysis for TECH
$72.52
+0.02
(+0.03%)
- 📈 Growth — 16/30
- 💰 Profitability — 18/20
- 🏦 Financial Health — 17/20
- 💵 Valuation — 14/20
- ⚠️ Risk — 4/10
Overall Score: 71/100
Summary:
📈 Growth & Financial Trajectory
- Over the 8 quarters, Revenues started at $316.964M in 2025-Q1 and ended at $321.192M in 2026-Q4, a modest gain. Net Income moved from about $33.6M to $54.6M, up ~62%. Gross Margin holds in the mid-60s range, and Operating Margin improved from the low teens in 2025 to the mid-20s by 2026, signaling stronger operating leverage.
💰 Margins & Cash Flow
- Gross Margin remains robust around the mid-60s percent; Operating Margin trends up, reflecting better cost control and scale. Net Cash Flow From Operating Activities consistently in the high tens of millions per quarter, with occasional financing outflows; free cash flow generation is implied by positive operating cash flow relative to investing activity.
🛡️ Balance Sheet & Liquidity
- Balance sheet shows solid Equity around $2.0B and total Assets near $2.5B, with Current Assets roughly $0.6–0.7B and Current Liabilities around $0.14–0.17B in multiple quarters, supporting liquidity. Noncurrent liabilities are typically modest.
⚠️ Key Drivers & Risks
- Drivers: Biotech research tool demand and a stable product portfolio; Life sciences spending.
- Risks: Cyclicality of biotech budgets and potential valuation sensitivity to earnings pace.
📊 Key Financial Fundamentals
Valuation Multiples
Market Cap
$11.34B
P/E Ratio
62.34
Forward P/E
35.21
P/S Ratio
9.33
P/B Ratio
5.22
EV / EBITDA
32.28
Profitability & Returns
Gross Margin
66.24%
Operating Margin
20.73%
Net Margin
14.97%
ROE
8.90%
ROIC
7.97%
Financial Health & Liquidity
Current Ratio
4.55
Quick Ratio
3.35
Financial Scale & Cash Flow
Revenue
$1.22B
Net Income
$0.18B
FCF Yield
2.32%
Free Cash Flow
$0.26B
Total Debt To Equity
0.09